{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:40:55Z","timestamp":1792899655497,"version":"4.5.0"},"reference-count":61,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cardiovascular diseases keep being the leading cause of mortality in Spain. Efforts should be intensified to identify new risk factors that may contribute to increasing cardiovascular risk. Lipoprotein(a) (Lp(a)) has been associated with a higher risk for developing aortic valve stenosis, heart failure, ischemic stroke, ischemic heart disease and peripheral arterial disease. Hyperlipoproteinemia(a) is a common health problem. Between 10 and 30\u202f% of the world population have Lp(a) values exceeding 50\u202fmg\/dL. The scientific evidence provided in the recent years confirms an independent association between Lp(a) and the risk for having an arteriosclerotic cardiovascular event. This finding, added to the emergence of new specific therapies for\u00a0reducing Lp(a) has raised interest in the quantification of this lipoprotein. The objective of this paper was to perform a review of\u00a0the evidence available to identify the patients who will benefit from undergoing Lp(a) testing and determine the\u00a0recommended quantification methods, the desirable concentrations, and the role of Lp(a) determination in reclassifying the cardiovascular risk of patients.<\/jats:p>","DOI":"10.1515\/almed-2025-0034","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T07:54:36Z","timestamp":1740815676000},"page":"7-16","source":"Crossref","is-referenced-by-count":2,"title":["Fundamentals of lipoprotein(a) request and quantification in the clinical laboratory"],"prefix":"10.1515","volume":"6","author":[{"given":"Teresa Arrobas","family":"Velilla","sequence":"first","affiliation":[{"name":"Virgen Macarena University Hospital , Seville , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Fern\u00e1ndez","family":"Prendes","sequence":"additional","affiliation":[{"name":"Analysis and Clinical Biochemistry Service, Laboratori Cl\u00ednic Metropolitana Nord , Hospital Universitari Germans Trias i Pujol , Badalona, Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria Amig\u00f3","family":"Grau","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences , Rovira i Virgili University , Reus , Spain"},{"name":"Center for Biomedical Research in Diabetes and Associated Metabolic Diseases (CIBERDEM) , Instituto de Salud Carlos III , Madrid , Comunidad de Madrid , Spain"},{"name":"Biosfer Teslab , Reus , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Calmarza","sequence":"additional","affiliation":[{"name":"Service of Clinical Biochemistry , Miguel Servet University Hospital , Zaragoza , Arag\u00f3n , Spain"},{"name":"Centre for Networked Research in Cardiovascular Diseases (CIBERCV), Instituto de Investigacion Sanitaria Aragon , Zaragoza , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Cam\u00f3s","family":"Anguila","sequence":"additional","affiliation":[{"name":"Service of Clinical Biochemistry- Laboratori Cl\u00ednic Girona, Hospital Universitari de Girona Doctor Josep Trueta , Catalunya , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Candas","family":"Est\u00e9banez","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, Hospital of Barcelona , Barcelona , Catalunya , Spain"},{"name":"Faculty of Medicine , UVic-UCC , Vic , Spain"},{"name":"Faculty of Sciences , UVic-UCC , Vic , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9 Castro","family":"Castro","sequence":"additional","affiliation":[{"name":"Biochemistry Core, Laboratori Cl\u00ednic Territorial Metropolitana Sud , Bellvitge University Hospital , L\u2019Hospitalet de Llobregat , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ceacero","sequence":"additional","affiliation":[{"name":"Biochemistry Core, Laboratori Cl\u00ednic Territorial Metropolitana Sud , Bellvitge University Hospital , L\u2019Hospitalet de Llobregat , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Gonz\u00e1lez","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Service of Clinical Biochemistry , 12 de Octubre University Hospital , Madrid , Autonomous Community of Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Mart\u00edn","family":"Palencia","sequence":"additional","affiliation":[{"name":"Service of Clinical Biochemistry , University Hospital of Burgos , Burgos , Castilla y Le\u00f3n , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Puzo","family":"Foncillas","sequence":"additional","affiliation":[{"name":"Service of Clinical Biochemistry, Unit of Lipids , Hospital General Universitario San Jorge de Huesca, General University Hospital , Huesca , Spain"},{"name":"Faculty of Life Sciences and Sports , Huesca , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Romero","family":"Rom\u00e1n","sequence":"additional","affiliation":[{"name":"General University Hospital of Albacete , Albacete , Castilla-La Mancha , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"2025032722230574090_j_almed-2025-0034_ref_001","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Disponible en. https:\/\/www.ine.es\/dynt3\/inebase\/es\/index.htm?padre=4858 fecha consulta 21\/02\/2024."},{"key":"2025032722230574090_j_almed-2025-0034_ref_002","doi-asserted-by":"crossref","unstructured":"Kamstrup, PR. Lipoprote\u00edna(a) y enfermedad cardiovascular. Clin Chem 2021;67:154\u201366. https:\/\/doi.org\/10.1093\/clinchem\/hvaa247.","DOI":"10.1093\/clinchem\/hvaa247"},{"key":"2025032722230574090_j_almed-2025-0034_ref_003","doi-asserted-by":"crossref","unstructured":"Lampsas, S, Xenou, M, Oikonomou, E, Pantelidis, P, Lysandrou, A, Sarantos, S, et al.. Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment. Molecules 2023;28:969. https:\/\/doi.org\/10.3390\/molecules28030969.","DOI":"10.3390\/molecules28030969"},{"key":"2025032722230574090_j_almed-2025-0034_ref_004","doi-asserted-by":"crossref","unstructured":"Leibundgut, G, Scipione, C, Yin, H, Schneider, M, Boffa, MB, Green, S, et al.. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res 2013;54:2815\u201330. https:\/\/doi.org\/10.1194\/jlr.m040733.","DOI":"10.1194\/jlr.M040733"},{"key":"2025032722230574090_j_almed-2025-0034_ref_005","doi-asserted-by":"crossref","unstructured":"Tsimikas, S, Fazio, S, Ferdinand, KC, Ginsberg, HN, Koschinsky, ML, Marcovina, SM, et al.. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol 2018;71:177\u201392. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.014.","DOI":"10.1016\/j.jacc.2017.11.014"},{"key":"2025032722230574090_j_almed-2025-0034_ref_006","doi-asserted-by":"crossref","unstructured":"P\u00e9rez de Isla, L, Alonso, R, Mata, N, Fern\u00e1ndez-P\u00e9rez, C, Mu\u00f1iz, O, D\u00edaz-D\u00edaz, JL, et al.. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART Registry (Spanish familial hypercholesterolemia cohort study). Circulation 2017;135:2133\u201344. https:\/\/doi.org\/10.1161\/circulationaha.116.024541.","DOI":"10.1161\/CIRCULATIONAHA.116.024541"},{"key":"2025032722230574090_j_almed-2025-0034_ref_007","doi-asserted-by":"crossref","unstructured":"Arrobas Velilla, T, Fabiani de la Iglesia, J, Mart\u00edn P\u00e9rez, S, Calbo Caballos, L, G\u00f3mez Barrado, JJ, Le\u00f3n Justel, A, et al., en representaci\u00f3n del Grupo de Trabajo de Riesgo Cardiovascular de la Sociedad Andaluza de An\u00e1lisis Cl\u00ednicos y colaboradores. Lipoprotein(a) in a selection of hospitals in Andalusia and Extremadura. Underdiagnosed and underused? Rev Esp Cardiol (Engl Ed) 2022;75:844\u20135. https:\/\/doi.org\/10.1016\/j.rec.2022.05.001 (English, Spanish).","DOI":"10.1016\/j.rec.2022.05.001"},{"key":"2025032722230574090_j_almed-2025-0034_ref_008","doi-asserted-by":"crossref","unstructured":"Berg, K. A new serum type system in man\u00a0\u2013 the LP system. Acta Pathol Microbiol Scand 1963;59:369\u201382. https:\/\/doi.org\/10.1111\/j.1699-0463.1963.tb01808.x.","DOI":"10.1111\/j.1699-0463.1963.tb01808.x"},{"key":"2025032722230574090_j_almed-2025-0034_ref_009","doi-asserted-by":"crossref","unstructured":"Jawi, MM, Frohlich, J, Chan, SY. Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. J Lipids 2020;2020:3491764. https:\/\/doi.org\/10.1155\/2020\/3491764.","DOI":"10.1155\/2020\/3491764"},{"key":"2025032722230574090_j_almed-2025-0034_ref_010","doi-asserted-by":"crossref","unstructured":"Nguyen, TT, Ellefson, RD, Hodge, DO, Bailey, KR, Kottke, TE, Abu-Lebdeh, HS. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997;96:1390\u20137. https:\/\/doi.org\/10.1161\/01.cir.96.5.1390.","DOI":"10.1161\/01.CIR.96.5.1390"},{"key":"2025032722230574090_j_almed-2025-0034_ref_011","doi-asserted-by":"crossref","unstructured":"Patel, AP, Wang, M, Pirruccello, JP, Ellinor, PT, Ng, K, Kathiresan, S, et al.. Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large National Biobank. Arterioscler Thromb Vasc Biol 2021;41:465\u201374. https:\/\/doi.org\/10.1161\/atvbaha.120.315291.","DOI":"10.1161\/ATVBAHA.120.315291"},{"key":"2025032722230574090_j_almed-2025-0034_ref_012","doi-asserted-by":"crossref","unstructured":"Coassin, S, Kronenberg, F. Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene. Atherosclerosis 2022;349:17\u201335. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.003.","DOI":"10.1016\/j.atherosclerosis.2022.04.003"},{"key":"2025032722230574090_j_almed-2025-0034_ref_013","doi-asserted-by":"crossref","unstructured":"Utermann, G. The mysteries of lipoprotein(a). Science 1989;246:904\u201310. https:\/\/doi.org\/10.1126\/science.2530631.","DOI":"10.1126\/science.2530631"},{"key":"2025032722230574090_j_almed-2025-0034_ref_014","doi-asserted-by":"crossref","unstructured":"Pas\u0142awska, A, Tomasik, PJ. Lipoprotein(a)-60 years later-what do we know? Cells 2023;12:2472. https:\/\/doi.org\/10.3390\/cells12202472.","DOI":"10.3390\/cells12202472"},{"key":"2025032722230574090_j_almed-2025-0034_ref_015","doi-asserted-by":"crossref","unstructured":"Tsimikas, S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 2017;69:692\u2013711. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.042.","DOI":"10.1016\/j.jacc.2016.11.042"},{"key":"2025032722230574090_j_almed-2025-0034_ref_016","doi-asserted-by":"crossref","unstructured":"Saeed, A, Kinoush, S, Virani, SS. Lipoprotein (a): recent updates on a unique lipoprotein. Curr Atheroscler Rep 2021;23:41. https:\/\/doi.org\/10.1007\/s11883-021-00940-5.","DOI":"10.1007\/s11883-021-00940-5"},{"key":"2025032722230574090_j_almed-2025-0034_ref_017","doi-asserted-by":"crossref","unstructured":"Kronenberg, F, Utermann, G. Lipoprotein(a): resurrected by genetics. J Intern Med 2013;273:6\u201330. https:\/\/doi.org\/10.1111\/j.1365-2796.2012.02592.x.","DOI":"10.1111\/j.1365-2796.2012.02592.x"},{"key":"2025032722230574090_j_almed-2025-0034_ref_018","unstructured":"Esteban-Sal\u00e1n, M, Aguilar-Doreste, J\u00c1, Gerique, JAG, Rom\u00e1n, CR, Castro-Castro, MJ, Calmarza, PC, et al.. Lipoprote\u00edna (a): factor de riesgo emergente de enfermedad cardiovascular. Documentos de la SEQC 2013:39\u201346."},{"key":"2025032722230574090_j_almed-2025-0034_ref_019","doi-asserted-by":"crossref","unstructured":"Ruscica, M, Sirtori, CR, Corsini, A, Watts, GF, Sahebkar, A. Lipoprotein(a): knowns, unknowns and uncertainties. Pharmacol Res 2021;173:105812. https:\/\/doi.org\/10.1016\/j.phrs.2021.105812.","DOI":"10.1016\/j.phrs.2021.105812"},{"key":"2025032722230574090_j_almed-2025-0034_ref_020","doi-asserted-by":"crossref","unstructured":"Song, X, Sun, H, Chen, K. Association of lipoprotein(a) concentrations and apolipoprotein(a) isoform with coronary artery disease stratification in Han Chinese. Clin Lab 2022;68:1. https:\/\/doi.org\/10.7754\/clin.lab.2022.211232.","DOI":"10.7754\/Clin.Lab.2022.211232"},{"key":"2025032722230574090_j_almed-2025-0034_ref_021","doi-asserted-by":"crossref","unstructured":"Schmidt, K, Noureen, A, Kronenberg, F, Utermann, G. Structure, function, and genetics of lipoprotein (a). J Lipid Res 2016;57:1339\u201359. https:\/\/doi.org\/10.1194\/jlr.r067314.","DOI":"10.1194\/jlr.R067314"},{"key":"2025032722230574090_j_almed-2025-0034_ref_022","doi-asserted-by":"crossref","unstructured":"Tsimikas, S, Clopton, P, Brilakis, ES, Marcovina, SM, Khera, A, Miller, ER, et al.. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race\/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation 2009;119:1711\u20139. https:\/\/doi.org\/10.1161\/circulationaha.108.836940.","DOI":"10.1161\/CIRCULATIONAHA.108.836940"},{"key":"2025032722230574090_j_almed-2025-0034_ref_023","doi-asserted-by":"crossref","unstructured":"Delgado-Lista, J, Mostaza, JM, Arrobas-Velilla, T, Blanco-Vaca, F, Masana, L, Pedro-Botet, J, et al.. Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis. Literature review and recommendations for clinical practice. Cl\u00edn Invest Arterioscler 2024;36:243\u201366. https:\/\/doi.org\/10.1016\/j.artere.2024.07.008.","DOI":"10.1016\/j.artere.2024.07.008"},{"key":"2025032722230574090_j_almed-2025-0034_ref_024","doi-asserted-by":"crossref","unstructured":"Marcovina, SM, Koschinsky, ML, Albers, JJ, Skarlatos, S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 2003;49:1785\u201396. https:\/\/doi.org\/10.1373\/clinchem.2003.023689.","DOI":"10.1373\/clinchem.2003.023689"},{"key":"2025032722230574090_j_almed-2025-0034_ref_025","doi-asserted-by":"crossref","unstructured":"Cegla, J, Neely, RDG, France, M, Ferns, G, Byrne, CD, Halcox, J, et al.. HEART UK consensus statement on lipoprotein(a): a call to action. Atherosclerosis 2019;291:62\u201370. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.10.011.","DOI":"10.1016\/j.atherosclerosis.2019.10.011"},{"key":"2025032722230574090_j_almed-2025-0034_ref_026","doi-asserted-by":"crossref","unstructured":"Kronenberg, F, Mora, S, Stroes, ESG, Ference, BA, Arsenault, BJ, Berglund, L, et al.. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022;43:3925\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361.","DOI":"10.1093\/eurheartj\/ehac361"},{"key":"2025032722230574090_j_almed-2025-0034_ref_027","doi-asserted-by":"crossref","unstructured":"Arnett, DK, Blumenthal, RS, Albert, MA, Buroker, AB, Goldberger, ZD, Hahn, EJ, et al.. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation [Internet] 2019;140:3\u201399, https:\/\/doi.org\/10.1161\/cir.0000000000000677.","DOI":"10.1161\/CIR.0000000000000724"},{"key":"2025032722230574090_j_almed-2025-0034_ref_028","doi-asserted-by":"crossref","unstructured":"Wilson, DP, Jacobson, TA, Jones, PH, Koschinsky, ML, McNeal, CJ, Nordestgaard, BG, et al.. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2022;16:e77\u201395. https:\/\/doi.org\/10.1016\/j.jacl.2022.08.007.","DOI":"10.1016\/j.jacl.2022.08.007"},{"key":"2025032722230574090_j_almed-2025-0034_ref_029","doi-asserted-by":"crossref","unstructured":"Durlach, V, Bonnefont-Rousselot, D, Boccara, F, Varret, M, Charcosset, MDF, Cariou, B, et al.. Lipoprotein(a): pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Soci\u00e9t\u00e9 Francophone d\u2019Ath\u00e9roscl\u00e9rose (NSFA). Arch Cardiovasc Dis 2021;114:828\u201347. https:\/\/doi.org\/10.1016\/j.acvd.2021.10.009.","DOI":"10.1016\/j.acvd.2021.10.009"},{"key":"2025032722230574090_j_almed-2025-0034_ref_030","doi-asserted-by":"crossref","unstructured":"Mach, F, Baigent, C, Catapano, AL, Koskinas, KC, Casula, M, Badimon, L, et al.. ESC Scientific Document Group. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"2025032722230574090_j_almed-2025-0034_ref_031","doi-asserted-by":"crossref","unstructured":"Pearson, GJ, Thanassoulis, G, Anderson, TJ, Barry, AR, Couture, P, Dayan, N, et al.. 2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol 2021;37:1129\u201350. https:\/\/doi.org\/10.1016\/j.cjca.2021.03.016.","DOI":"10.1016\/j.cjca.2021.03.016"},{"key":"2025032722230574090_j_almed-2025-0034_ref_032","doi-asserted-by":"crossref","unstructured":"Arrobas Velilla, T, Guijarro, C, Campuzano Ruiz, R, Rodr\u00edguez Pi\u00f1ero, M, Valderrama Marcos, JF, P\u00e9rez P\u00e9rez, A, et al.. Consensus document for lipid profile determination and reporting in Spanish clinical laboratories. What parameters should be included in a basic lipid profile? Cl\u00edn Invest Arterioscler 2023;35:91\u2013100. https:\/\/doi.org\/10.1016\/j.artere.2023.05.001.","DOI":"10.1016\/j.neurop.2023.100126"},{"key":"2025032722230574090_j_almed-2025-0034_ref_033","doi-asserted-by":"crossref","unstructured":"Delgado-Lista, J, Mostaza, JM, Arrobas-Velilla, T, Blanco-Vaca, F, Masana, L, Pedro-Botet, J, et al.. Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis. Literature review and recommendations for clinical practice. Cl\u00edn Invest Arterioscler 2024;36:243\u201366. https:\/\/doi.org\/10.1016\/j.artere.2024.07.008.","DOI":"10.1016\/j.artere.2024.07.008"},{"key":"2025032722230574090_j_almed-2025-0034_ref_034","doi-asserted-by":"crossref","unstructured":"Virani, SS, Koschinsky, ML, Maher, L, Mehta, A, Orringer, CE, Santos, RD, et al.. Global think tank on the clinical considerations and management of lipoprotein(a): the top questions and answers regarding what clinicians need to know. Prog Cardiovasc Dis 2022;73:32\u201340. https:\/\/doi.org\/10.1016\/j.pcad.2022.01.002.","DOI":"10.1016\/j.pcad.2022.01.002"},{"key":"2025032722230574090_j_almed-2025-0034_ref_035","doi-asserted-by":"crossref","unstructured":"Kohn, B, Ashraf, AP, Wilson, DP. Should lipoprotein(a) be measured in youth? J Pediatr 2021;228:285\u20139. https:\/\/doi.org\/10.1016\/j.jpeds.2020.08.042.","DOI":"10.1016\/j.jpeds.2020.08.042"},{"key":"2025032722230574090_j_almed-2025-0034_ref_036","doi-asserted-by":"crossref","unstructured":"deBoer, LMde, Hof, MH, Wiegman, A, Stroobants, AK, Kastelein, JJP, Hutten, BA. Lipoprotein(a) levels from childhood to adulthood: data in nearly 3,000 children who visited a pediatric lipid clinic. Atherosclerosis 2022;349:227\u201332. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.03.004.","DOI":"10.1016\/j.atherosclerosis.2022.03.004"},{"key":"2025032722230574090_j_almed-2025-0034_ref_037","doi-asserted-by":"crossref","unstructured":"Alankar, A, Brar, PC, Kohn, B. Lipoprotein(a): a case for universal screening in youth. Curr Atheroscler Rep 2023;25:487\u201393. https:\/\/doi.org\/10.1007\/s11883-023-01120-3.","DOI":"10.1007\/s11883-023-01120-3"},{"key":"2025032722230574090_j_almed-2025-0034_ref_038","doi-asserted-by":"crossref","unstructured":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011;128:S213\u201356. https:\/\/doi.org\/10.1542\/peds.2009-2107c.","DOI":"10.1542\/peds.2009-2107C"},{"key":"2025032722230574090_j_almed-2025-0034_ref_039","doi-asserted-by":"crossref","unstructured":"Enkhmaa, B, Anuurad, E, Berglund, L. Lipoprotein(a): impact by ethnicity and environmental and medical conditions. J Lipid Res 2016;57:1111\u201325. https:\/\/doi.org\/10.1194\/jlr.r051904.","DOI":"10.1194\/jlr.R051904"},{"key":"2025032722230574090_j_almed-2025-0034_ref_040","doi-asserted-by":"crossref","unstructured":"Ghouse, J, Ahlberg, G, Albertsen Rand, S, Salling Olesen, M, Vilhjalmsson, B, Stender, S, et al.. Within-person stability of lipoprotein(a) concentration. Eur Heart J 2024;8:ehae652. https:\/\/doi.org\/10.1093\/eurheartj\/ehae652.","DOI":"10.1093\/eurheartj\/ehae652"},{"key":"2025032722230574090_j_almed-2025-0034_ref_041","doi-asserted-by":"crossref","unstructured":"Matta, MG, Schreier, L, Lavalle-Cobo, A, Garcia-Zamora, S, Ferraresi, A, Madsen, A, et al.. Temporal variability of Lp(a) in clinically stable patients: implications for cardiovascular risk assessment. Med Clin 2024;163:436\u201341. https:\/\/doi.org\/10.1016\/j.medcle.2024.05.018. English, Spanish.","DOI":"10.1016\/j.medcle.2024.05.018"},{"key":"2025032722230574090_j_almed-2025-0034_ref_042","doi-asserted-by":"crossref","unstructured":"Enkhmaa, B, Berglund, L. Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis 2022;349:53\u201362. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.006.","DOI":"10.1016\/j.atherosclerosis.2022.04.006"},{"key":"2025032722230574090_j_almed-2025-0034_ref_043","doi-asserted-by":"crossref","unstructured":"Kronenberg, F. Lipoprotein(a) measurement issues: are we making a mountain out of a molehill? Atherosclerosis 2022;349:123\u201335. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.008.","DOI":"10.1016\/j.atherosclerosis.2022.04.008"},{"key":"2025032722230574090_j_almed-2025-0034_ref_044","doi-asserted-by":"crossref","unstructured":"Scharnagl, H, Stojakovic, T, Dieplinger, B, Dieplinger, H, Erhart, G, Kostner, GM, et al.. Comparison of lipoprotein (a)\u00a0serum concentrations measured by six commercially available immunoassays. Atherosclerosis 2019;289:206\u201313. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.08.015.","DOI":"10.1016\/j.atherosclerosis.2019.08.015"},{"key":"2025032722230574090_j_almed-2025-0034_ref_045","doi-asserted-by":"crossref","unstructured":"Tsimikas, S, Fazio, S, Viney, NJ, Xia, S, Witztum, JL, Marcovina, SM. Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. J Clin Lipidol 2018;12:1313\u201323. https:\/\/doi.org\/10.1016\/j.jacl.2018.07.003. Epub 2018 Jul 20. PMID: 30100157.","DOI":"10.1016\/j.jacl.2018.07.003"},{"key":"2025032722230574090_j_almed-2025-0034_ref_046","doi-asserted-by":"crossref","unstructured":"Ruhaak, LR, Cobbaert, CM. Quantifying apolipoprotein(a) in the era of proteoforms and precision medicine. Clin Chim Acta 2020;511:260\u20138. https:\/\/doi.org\/10.1016\/j.cca.2020.10.010.","DOI":"10.1016\/j.cca.2020.10.010"},{"key":"2025032722230574090_j_almed-2025-0034_ref_047","doi-asserted-by":"crossref","unstructured":"Dikaios, I, Althaus, H, Angles-Cano, E, Ceglarek, U, Coassin, S, Cobbaert, CM, et al.. Commutability assessment of candidate reference materials for lipoprotein(a) by comparison of a MS-based candidate reference measurement procedure with immunoassays. Clin Chem 2023;69:262\u201372. https:\/\/doi.org\/10.1093\/clinchem\/hvac203.","DOI":"10.1093\/clinchem\/hvac203"},{"key":"2025032722230574090_j_almed-2025-0034_ref_048","doi-asserted-by":"crossref","unstructured":"Marcovina, SM, Albers, JJ. Lipoprotein (a)\u00a0measurements for clinical application. J Lipid Res 2016;57:526\u201337. https:\/\/doi.org\/10.1194\/jlr.r061648.","DOI":"10.1194\/jlr.R061648"},{"key":"2025032722230574090_j_almed-2025-0034_ref_049","doi-asserted-by":"crossref","unstructured":"Kronenberg, F. Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region. Clin Res Cardiol Suppl 2019;14:5\u201312. https:\/\/doi.org\/10.1007\/s11789-019-00093-5.","DOI":"10.1007\/s11789-019-00093-5"},{"key":"2025032722230574090_j_almed-2025-0034_ref_050","doi-asserted-by":"crossref","unstructured":"Tsimikas, S, Fazio, S, Ferdinand, KC, Ginsberg, HN, Koschinsky, ML, Marcovina, SM, et al.. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol 2018;71:177\u201392. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.014.","DOI":"10.1016\/j.jacc.2017.11.014"},{"key":"2025032722230574090_j_almed-2025-0034_ref_051","doi-asserted-by":"crossref","unstructured":"Cegla, J, France, M, Marcovina, SM, Neely, RDG. Lp(a): when and how to measure it. Ann Clin Biochem 2020;58:16\u201321. https:\/\/doi.org\/10.1177\/0004563220968473.","DOI":"10.1177\/0004563220968473"},{"key":"2025032722230574090_j_almed-2025-0034_ref_052","doi-asserted-by":"crossref","unstructured":"Pint\u00f3, X, Masana, L, Civeira, F, Real, J, Ibarretxe, D, Candas, B, et al.. Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale\u00ae). Cl\u00edn Invest Arterioscler 2020;32:219\u201329. https:\/\/doi.org\/10.1016\/j.artere.2020.04.001.","DOI":"10.1016\/j.artere.2020.04.001"},{"key":"2025032722230574090_j_almed-2025-0034_ref_053","doi-asserted-by":"crossref","unstructured":"Puig-Jov\u00e9, C, Castelblanco, E, Falguera, M, Hern\u00e1ndez, M, Soldevila, B, Juli\u00e1n, MT, et al.. Perfil lipoproteico avanzado en individuos con metabolismo de la glucosa normal e alterado. Rev Esp Cardiol 2022;75:22\u201330. https:\/\/doi.org\/10.1016\/j.recesp.2021.02.013.","DOI":"10.1016\/j.recesp.2021.02.013"},{"key":"2025032722230574090_j_almed-2025-0034_ref_054","doi-asserted-by":"crossref","unstructured":"Matyus, SP, Braun, PJ, Wolak-Dinsmore, J, Jeyarajah, EJ, Shalaurova, I, Xu, Y, et al.. NMR measurement of LDL particle number using the Vantera\u00ae Clinical Analyzer. Clin Biochem 2014;47:203\u201310. https:\/\/doi.org\/10.1016\/j.clinbiochem.2014.07.015.","DOI":"10.1016\/j.clinbiochem.2014.07.015"},{"key":"2025032722230574090_j_almed-2025-0034_ref_055","doi-asserted-by":"crossref","unstructured":"Yeang, C, Witztum, JL, Tsimikas, S. \u2018LDLC\u2019=LDL-C+Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin\/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol 2015;26:169\u201378. https:\/\/doi.org\/10.1097\/mol.0000000000000171.","DOI":"10.1097\/MOL.0000000000000171"},{"key":"2025032722230574090_j_almed-2025-0034_ref_056","doi-asserted-by":"crossref","unstructured":"Marcovina, SM, Navabi, N, Allen, S, Gonen, A, Witztum, JL, Tsimikas, S. Development and validation of an isoform-independent monoclonal antibody-based ELISA for measurement of lipoprotein(a). J Lipid Res 2022;63:100239. https:\/\/doi.org\/10.1016\/j.jlr.2022.100239.","DOI":"10.1016\/j.jlr.2022.100239"},{"key":"2025032722230574090_j_almed-2025-0034_ref_057","doi-asserted-by":"crossref","unstructured":"Scanu, AM. Lipoprotein(a), Friedewald formula, and NCEP guidelines. National Cholesterol Education Program. Am J Cardiol 2001;87:608\u20139, A9. https:\/\/doi.org\/10.1016\/s0002-9149(00)01440-5.","DOI":"10.1016\/S0002-9149(00)01440-5"},{"key":"2025032722230574090_j_almed-2025-0034_ref_058","doi-asserted-by":"crossref","unstructured":"Bergmark, BA, O\u2019Donoghue, ML, Murphy, SA, Kuder, JF, Ezhov, MV, Ce\u0161ka, R, et al.. An exploratory analysis of proprotein convertase subtilisin\/kexin type 9 inhibition and aortic stenosis in the FOURIER trial. JAMA Cardiol 2020;5:709\u201313. https:\/\/doi.org\/10.1001\/jamacardio.2020.0728.","DOI":"10.1001\/jamacardio.2020.0728"},{"key":"2025032722230574090_j_almed-2025-0034_ref_059","doi-asserted-by":"crossref","unstructured":"Yeang, C, Witztum, JL, Tsimikas, S. Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. J Lipid Res 2021;62:100053. https:\/\/doi.org\/10.1016\/j.jlr.2021.100053.","DOI":"10.1016\/j.jlr.2021.100053"},{"key":"2025032722230574090_j_almed-2025-0034_ref_060","doi-asserted-by":"crossref","unstructured":"Langlois, MR, Nordestgaard, BG, Langsted, A, Chapman, MJ, Aakre, KM, Baum, H, et al., European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med 2020;58:496\u2013517. https:\/\/doi.org\/10.1515\/cclm-2019-1253.","DOI":"10.1515\/cclm-2019-1253"},{"key":"2025032722230574090_j_almed-2025-0034_ref_061","doi-asserted-by":"crossref","unstructured":"Baigent, C, Catapano, AL, Koskinas, KC, Casula, M, Badimon, L, et al., Authors\/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205, https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.08.014.\u201d","DOI":"10.1016\/j.atherosclerosis.2019.08.014"}],"container-title":["Advances in Laboratory Medicine \/ Avances en Medicina de Laboratorio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/almed-2025-0034\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/almed-2025-0034\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T08:41:35Z","timestamp":1743151295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/almed-2025-0034\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,2]]},"published-print":{"date-parts":[[2025,3,28]]}},"alternative-id":["10.1515\/almed-2025-0034"],"URL":"https:\/\/doi.org\/10.1515\/almed-2025-0034","relation":{},"ISSN":["2628-491X"],"issn-type":[{"value":"2628-491X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}